Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study

Publisher： Karger

E-ISSN： 1423-0194|105|1|26-34

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.105, Iss.1, 2016-05, pp. : 26-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review

By  

Neuroendocrinology, Vol. 93, Iss. 4, 2011-02 ,pp. : 223-229

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 103, Iss. 2, 2016-01 ,pp. : 153-171

Karger

Access to resources Recommend Favorite

A Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours

By  

Neuroendocrinology, Vol. 105, Iss. 3, 2017-04 ,pp. : 320-330

Karger

Access to resources Recommend Favorite

Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin

By  

Neuroendocrinology, Vol. 98, Iss. 2, 2013-08 ,pp. : 137-143

Karger

Access to resources Recommend Favorite

From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 94, Iss. 3, 2011-08 ,pp. : 177-190

Karger

Access to resources Recommend Favorite